Equities research analysts expect Nevro Corp (NYSE:NVRO) to report ($0.85) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Nevro’s earnings, with estimates ranging from ($1.03) to ($0.53). Nevro posted earnings of ($0.35) per share in the same quarter last year, which would suggest a negative year over year growth rate of 142.9%. The firm is expected to announce its next earnings report on Thursday, August 1st.

According to Zacks, analysts expect that Nevro will report full year earnings of ($3.69) per share for the current fiscal year, with EPS estimates ranging from ($4.23) to ($2.88). For the next financial year, analysts anticipate that the firm will report earnings of ($2.65) per share, with EPS estimates ranging from ($3.64) to ($1.21). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Nevro.

Nevro (NYSE:NVRO) last announced its earnings results on Thursday, May 9th. The medical equipment provider reported ($1.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.79). Nevro had a negative net margin of 19.79% and a negative return on equity of 31.84%. The business had revenue of $82.10 million for the quarter, compared to analysts’ expectations of $87.47 million. During the same period in the prior year, the business earned ($0.59) earnings per share. The company’s revenue for the quarter was down 6.3% compared to the same quarter last year.

Several equities research analysts have recently issued reports on the company. JMP Securities decreased their target price on Nevro from $80.00 to $70.00 and set a “market outperform” rating for the company in a research report on Friday, May 10th. Zacks Investment Research lowered Nevro from a “hold” rating to a “sell” rating in a research report on Wednesday, February 27th. Canaccord Genuity lowered Nevro from a “buy” rating to a “hold” rating and decreased their target price for the company from $62.00 to $50.00 in a research report on Friday, May 10th. Bank of America raised Nevro from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $50.00 to $70.00 in a report on Wednesday, March 20th. Finally, BMO Capital Markets lowered Nevro from an “outperform” rating to a “market perform” rating in a report on Friday, February 22nd. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $57.83.

Shares of Nevro stock traded up $3.92 during trading hours on Wednesday, hitting $62.26. 923,951 shares of the company’s stock traded hands, compared to its average volume of 721,233. Nevro has a 12-month low of $34.75 and a 12-month high of $86.75. The firm has a market cap of $1.77 billion, a PE ratio of -38.24 and a beta of 0.18. The company has a debt-to-equity ratio of 0.83, a current ratio of 6.30 and a quick ratio of 4.87.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers boosted its stake in Nevro by 46.0% in the 4th quarter. Rhumbline Advisers now owns 39,058 shares of the medical equipment provider’s stock worth $1,519,000 after purchasing an additional 12,301 shares during the period. Partner Fund Management L.P. bought a new stake in shares of Nevro during the 4th quarter valued at about $21,627,000. Oppenheimer Asset Management Inc. bought a new stake in shares of Nevro during the 4th quarter valued at about $113,000. MetLife Investment Advisors LLC boosted its position in shares of Nevro by 55.3% during the 3rd quarter. MetLife Investment Advisors LLC now owns 20,240 shares of the medical equipment provider’s stock valued at $1,154,000 after acquiring an additional 7,210 shares during the last quarter. Finally, Gabelli Funds LLC boosted its position in shares of Nevro by 8.2% during the 4th quarter. Gabelli Funds LLC now owns 157,500 shares of the medical equipment provider’s stock valued at $6,125,000 after acquiring an additional 12,000 shares during the last quarter.

Nevro Company Profile

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Further Reading: Portfolio Manager

Get a free copy of the Zacks research report on Nevro (NVRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.